In good news, the US Food and Drug Administration approved, on Monday, the first home medicine to treat vitiligo in a breakthrough to treat the condition that affects millions of Americans.
And Opzelura, developed by the American company Wilmington, is a medical cream that can be applied directly to discoloration spots on the skin of people aged 12 and over, according to the British newspaper, “Daily Mail”.
It is noteworthy that this is the first such drug to receive such approval.
After regarding 6 months
In addition, many patients in clinical trials regained their pigmentation following regarding 6 months of twice daily use of the cream, which showed stronger results following a full year of treatment.
“We are proud of the scientists and development teams that made this achievement possible, and we are delighted that eligible vitiligo patients now have the option to treat re-pigmentation,” said Hervé Houbinot, CEO of the company.
(Istok)
How to use it
The cream is applied to non-pigmented spots of the skin twice a day. It should not be used on more than 10% of the body’s surface area.
It may take up to 24 weeks for the drug to show effectiveness in many patients. For others, it may take up to a year to reach its full potential.
(Istok)
promising results
In addition, the drug showed promising results in a phase III clinical trial, which was recently completed and included 600 participants. Those who used the cream showed a significant improvement in their skin tone, with half reaching the threshold of successful repigmentation following a year.
About 15% of the participants in the experiment managed to reach this point in just 24 weeks.
All skin types
Vitiligo affects people of all skin types, although it is more noticeable in people with dark skin. According to estimates, vitiligo affects 1-2 percent of the world’s population, although it is not fatal or contagious.
While it affects between 1.5 and 3 million Americans, according to official data. In some cases, the discolored spots are caused by the body’s inability to produce enough melanin.
